Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis

Takemori,Toshiyuki; Kawamoto,Teruya; Ueha,Takeshi; Toda,Mitsunori; Morishita,Masayuki; Kamata,Etsuko; Fukase,Naomasa; Hara,Hitomi; Fujiwara,Shuichi; Niikura,Takahiro; Kuroda,Ryosuke; Akisue,Toshihiro

doi:10.3892/or.2018.6608

Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis

Authors:
- Toshiyuki Takemori
- Teruya Kawamoto
- Takeshi Ueha
- Mitsunori Toda
- Masayuki Morishita
- Etsuko Kamata
- Naomasa Fukase
- Hitomi Hara
- Shuichi Fujiwara
- Takahiro Niikura
- Ryosuke Kuroda
- Toshihiro Akisue
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan, Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan, Department of Orthopaedic Surgery, Hyogo Rehabilitation Centre, Nishi-ku, Kobe 651-2181, Japan
Published online on: July 30, 2018 https://doi.org/10.3892/or.2018.6608
Pages: 2079-2087

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxia plays a significant role in cancer progression, including metastatic bone tumors. We previously reported that transcutaneous carbon dioxide (CO2) application could decrease tumor progression through the improvement of intratumor hypoxia. Therefore, we hypothesized that decreased hypoxia using transcutaneous CO2 could suppress progressive bone destruction in cancer metastasis. In the present study, we examined the effects of transcutaneous CO2 application on metastatic bone destruction using an animal model. The human breast cancer cell line MDA-MB-231 was cultured in vitro under three different oxygen conditions, and the effect of altered oxygen conditions on the expression of osteoclast-differentiation and osteolytic factors was assessed. An in vivo bone metastatic model of human breast cancer was created by intramedullary implantation of MDA-MB-231 cells into the tibia of nude mice, and treatment with 100% CO2 or a control was performed twice weekly for two weeks. Bone volume of the treated tibia was evaluated by micro-computed tomography (µCT), and following treatment, histological evaluation was performed by hematoxylin and eosin staining and immunohistochemical staining for hypoxia-inducible factor (HIF)-1α, osteoclast-differentiation and osteolytic factors, and tartrate-resistant acid phosphatase (TRAP) staining for osteoclast activity. In vitro experiments revealed that the mRNA expression of RANKL, PTHrP and IL-8 was significantly increased under hypoxic conditions and was subsequently reduced by reoxygenation. In vivo results by µCT revealed that bone destruction was suppressed by transcutaneous CO2, and that the expression of osteoclast-differentiation and osteolytic factors, as well as HIF-1α, was decreased in CO2-treated tumor tissues. In addition, multinucleated TRAP-positive osteoclasts were significantly decreased in CO2-treated tumor tissues. Hypoxic conditions promoted bone destruction in breast cancer metastasis, and reversal of hypoxia by transcutaneous CO2 application significantly inhibited metastatic bone destruction along with decreased osteoclast activity. The findings in this study strongly indicated that transcutaneous CO2 application could be a novel therapeutic strategy for treating metastatic bone destruction.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
3	Steinauer K, Huang DJ, Eppenberger-Castori S, Amann E and Güth U: Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy. J Bone Oncol. 3:54–60. 2014. View Article : Google Scholar : PubMed/NCBI
4	Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:4451–4458. 1999. View Article : Google Scholar : PubMed/NCBI
5	Kearns AE, Khosla S and Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 29:155–192. 2008. View Article : Google Scholar : PubMed/NCBI
6	Blair JM, Zhou H, Seibel MJ and Dunstan CR: Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. 3:41–49. 2006. View Article : Google Scholar : PubMed/NCBI
7	Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
8	Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D and Dougall WC: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 468:103–107. 2010. View Article : Google Scholar : PubMed/NCBI
9	Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ and Dougall WC: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 25:119–129. 2008. View Article : Google Scholar : PubMed/NCBI
10	Roodman GD and Dougall WC: RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 34:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
11	Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91:710–717. 1979. View Article : Google Scholar : PubMed/NCBI
12	Luu T, Chung C and Somlo G: Combining emerging agents in advanced breast cancer. Oncologist. 16:760–771. 2011. View Article : Google Scholar : PubMed/NCBI
13	Vyas S, Hameed S and Murugaraj V: Denosumab-associated osteonecrosis of the jaw - a case report. Dent Update. 41:449–450. 2014. View Article : Google Scholar : PubMed/NCBI
14	O'Halloran M, Boyd NM and Smith A: Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. Aust Dent J. 59:516–519. 2014. View Article : Google Scholar : PubMed/NCBI
15	Vaupel P and Harrison L: Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist. 9 Suppl 5:4–9. 2004. View Article : Google Scholar : PubMed/NCBI
16	Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
17	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
18	Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
19	Rundqvist H and Johnson RS: Tumour oxygenation: Implications for breast cancer prognosis. J Intern Med. 274:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
20	Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, et al: Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Res. 16:4582014. View Article : Google Scholar : PubMed/NCBI
21	de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS and Awada A: Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the ‘do ut des’ paradigm). Crit Rev Oncol Hematol. 59:40–50. 2006. View Article : Google Scholar : PubMed/NCBI
22	Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med. 9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
23	Tang ZN, Zhang F, Tang P, Qi XW and Jiang J: Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells. Biochem Biophys Res Commun. 408:411–416. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D and Agelaki S: Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 11:R842009. View Article : Google Scholar : PubMed/NCBI
25	Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M and Yoneda T: Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67:4157–4163. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hansen TN, Sonoda Y and McIlroy MB: Transfer of oxygen, nitrogen, and carbon dioxide through normal adult human skin. J Appl Physiol. 49:438–443. 1980. View Article : Google Scholar : PubMed/NCBI
27	Bohr C, Hasselbach K and Krogh A: Ueber emen in biologischen Bezuehung wichtigen Einfluss, den die Kohlen saurespannung des Blutes anf dessen Samerstoffbinding ubt. Arch Physiol. 16:402–412. 1904.
28	Sakai Y, Miwa M, Oe K, Ueha T, Koh A, Niikura T, Iwakura T, Lee SY, Tanaka M and Kurosaka M: A novel system for transcutaneous application of carbon dioxide causing an ‘artificial Bohr effect’ in the human body. PLoS One. 6:e241372011. View Article : Google Scholar : PubMed/NCBI
29	Onishi Y, Kawamoto T, Ueha T, Kishimoto K, Hara H, Fukase N, Toda M, Harada R, Minoda M, Sakai Y, et al: Transcutaneous application of carbon dioxide (CO₂) induces mitochondrial apoptosis in human malignant fibrous histiocytoma in vivo. PLoS One. 7:e491892012. View Article : Google Scholar : PubMed/NCBI
30	Harada R, Kawamoto T, Ueha T, Minoda M, Toda M, Onishi Y, Fukase N, Hara H, Sakai Y, Miwa M, et al: Reoxygenation using a novel CO₂ therapy decreases the metastatic potential of osteosarcoma cells. Exp Cell Res. 319:1988–1997. 2013. View Article : Google Scholar : PubMed/NCBI
31	Takeda D, Hasegawa T, Ueha T, Imai Y, Sakakibara A, Minoda M, Kawamoto T, Minamikawa T, Shibuya Y, Akisue T, et al: Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma in vivo. PLoS One. 9:e1005302014. View Article : Google Scholar : PubMed/NCBI
32	Onishi Y, Kawamoto T, Ueha T, Hara H, Fukase N, Toda M, Harada R, Sakai Y, Miwa M, Nishida K, et al: Transcutaneous application of Carbon Dioxide (CO₂) enhances chemosensitivity by reducing hypoxic conditions in human malignant fibrous histiocytoma. J Cancer Sci Ther. 4:174–181. 2012. View Article : Google Scholar
33	Bobrova TS, Kriukova IN, Voronina AN and Bassalyk LS: Study of the ‘continuous cell antigen’ and the human gastric mucosa. Biull Eksp Biol Med. 86:744–747. 1978.(In Russian). PubMed/NCBI
34	Okada Y, Ueno H, Katagiri M, Oneyama T, Shimomura K, Sakurai S, Mataga I, Moride M and Hasegawa H: Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology. 98:52–59. 2010. View Article : Google Scholar : PubMed/NCBI
35	Oe K, Ueha T, Sakai Y, Niikura T, Lee SY, Koh A, Hasegawa T, Tanaka M, Miwa M and Kurosaka M: The effect of transcutaneous application of carbon dioxide (CO₂) on skeletal muscle. Biochem Biophys Res Commun. 407:148–152. 2011. View Article : Google Scholar : PubMed/NCBI
36	Okada Y, Akisue T, Hara H, Kishimoto K, Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y and Kurosaka M: The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res. 30:3391–3395. 2010.PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−∆∆C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Modderman WE, Raap Tuinenburg-Bol AC and Nijweide PJ: Tartrate-resistant acid phosphatase is not an exclusive marker for mouse osteoclasts in cell culture. Bone. 12:81–87. 1991. View Article : Google Scholar : PubMed/NCBI
39	Boyde A, Maconnachie E, Reid SA, Delling G and Mundy GR: Scanning electron microscopy in bone pathology: Review of methods, potential and applications. Scan Electron Microsc. 4:1537–1554. 1986.
40	Kozlow W and Guise TA: Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 10:169–180. 2005. View Article : Google Scholar : PubMed/NCBI
41	Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D and Suva LJ: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 33:28–37. 2003. View Article : Google Scholar : PubMed/NCBI
42	Roodman GD: Biology of osteoclast activation in cancer. J Clin Oncol. 19:3562–3571. 2001. View Article : Google Scholar : PubMed/NCBI
43	Bryden AA, Hoyland JA, Freemont AJ, Clarke NW and George NJ: Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer. 86:322–325. 2002. View Article : Google Scholar : PubMed/NCBI
44	Miki T, Yano S, Hanibuchi M and Sone S: Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res. 12:209–217. 2000. View Article : Google Scholar : PubMed/NCBI
45	Rattigan Y, Hsu JM, Mishra PJ, Glod J and Banerjee D: Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res. 316:3417–3424. 2010. View Article : Google Scholar : PubMed/NCBI
46	Filippi I, Carraro F and Naldini A: Interleukin-1β affects MDAMB231 breast cancer cell migration under hypoxia: Role of HIF-1α and NFκB transcription factors. Mediators Inflamm. 2015:7894142015. View Article : Google Scholar : PubMed/NCBI
47	Tang ZN, Zhang F, Tang P, Qi XW and Jiang J: Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells Biochem Biophys Res Commun. 408:411–416. 2011.
48	Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
49	Vaupel P and Mayer A: Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
50	Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, et al: Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: A quantitative analysis of HIF-1. Arch Gynecol Obstet. 279:789–796. 2009. View Article : Google Scholar : PubMed/NCBI
51	Zeng W, Wan R, Zheng Y, Singh SR and Wei Y: Hypoxia, stem cells and bone tumor. Cancer Lett. 313:129–136. 2011. View Article : Google Scholar : PubMed/NCBI
52	Rohwer N and Cramer T: Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011. View Article : Google Scholar : PubMed/NCBI
53	Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN: Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 14:R62012. View Article : Google Scholar : PubMed/NCBI
54	Teicher BA: Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif Cells Blood Substit Immobil Biotechnol. 22:1109–1120. 1994. View Article : Google Scholar : PubMed/NCBI
55	Kawasoe Y, Yokouchi M, Ueno Y, Iwaya H, Yoshida H and Komiya S: Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma. Oncol Rep. 22:1045–1050. 2009.PubMed/NCBI
56	Kaanders JH, Bussink J and van der Kogel AJ: Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol. 14:233–240. 2004. View Article : Google Scholar : PubMed/NCBI
57	Budach W: Radiotherapy in patients with metastatic breast cancer. Eur J Cancer. 47 Suppl 3:S23–S27. 2011. View Article : Google Scholar : PubMed/NCBI
58	Blair DA, Glover WE and McArrdle L: The mechanism of the peripheral vasodilation following carbon dioxide inhalation in man. Clin Sci. 19:407–423. 1960.
59	Matz H, Orion E and Wolf R: Balneotherapy in dermatology. Dermatol Ther. 16:132–140. 2003. View Article : Google Scholar : PubMed/NCBI
60	Hartmann BR, Bassenge E, Pittler M and Hartmann BR: Effect of carbon dioxide-enriched water and fresh water on the cutaneous microcirculation and oxygen tension in the skin of the foot. Angiology. 48:337–343. 1997. View Article : Google Scholar : PubMed/NCBI
61	Koga T, Niikura T, Lee SY, Okumachi E, Ueha T, Iwakura T, Sakai Y, Miwa M, Kuroda R and Kurosaka M: Topical cutaneous CO₂ application by means of a novel hydrogel accelerates fracture repair in rats. J Bone Joint Surg Am. 96:2077–2084. 2014. View Article : Google Scholar : PubMed/NCBI
62	Trinkaus M, Ooi WS, Amir E, Popovic S, Kalina M, Kahn H, Singh G, Gainford MC and Clemons M: Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. Oncol Rep. 21:1153–1159. 2009.PubMed/NCBI
63	Chen YC, Sosnoski DM and Mastro AM: Breast cancer metastasis to the bone: Mechanisms of bone loss. Breast Cancer Res. 12:2152010. View Article : Google Scholar : PubMed/NCBI